Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome (MISTIC)
Multisystem Inflammatory Syndrome in Children

About this trial
This is an interventional treatment trial for Multisystem Inflammatory Syndrome in Children
Eligibility Criteria
Inclusion Criteria:
- Age: 18 to <21 years
Diagnosis: must meet ALL below criteria for COVID-19 related MIS-C as defined by the CDC.
- Age <21 years
- No alternative plausible diagnoses
- Positive for current or recent SARS-CoV-2 infection or COVID-19 exposure within the 4 weeks prior to the onset of symptoms. Exposure may be measure by RT-PCR, Serology, Antigen test, or History.
ALL of the following clinical symptoms:
Fever ≥38.0 degrees C for ≥24 hours or report of subjective fever lasting
- 24 hours
- Laboratory evidence of inflammation, including, but not limited to, one or more of the following: an elevated CRP, ESR, fibrinogen, procalcitonin, d- dimer, ferritin, LDH, or IL-6; elevated neutrophils, reduced lymphocytes, low albumin
- Clinically severe disease that requires hospitalization
- Multisystem (≥2) organ involvement:
I. Cardiovascular involvement (ANY of the listed criteria):
- Cardiac dysrhythmia or arrythmia (NOTE: patients with prolonged QT interval or unstable dys/arrythmias are not eligible)
- Ejection fraction 35%-<55%
- Pulmonary edema due to left heart failure
- Pericarditis or pericardial effusion (not requiring drainage)
- B-type natriuretic peptide (BNP) >400 pg/mL
- Elevated troponin (based on the upper limit of normal for the laboratory running the assay)
- Receipt of vasopressor or vasoactive support
II. Respiratory Involvement (includes ANY of the listed criteria)
- Receipt of mechanical ventilation or any type of supplemental oxygen (or increased support for patients receiving respiratory support at baseline)
- Pulmonary infiltrates on chest radiograph
- Lower respiratory infection
- Pleural effusion (not requiring chest tube)
- Pneumothorax (not requiring chest tube)
III. Ophthalmologic involvement
- Iritis or uveitis
IV. Gastrointestinal involvement (includes ANY of the listed criteria)
- Nausea/vomiting
- Diarrhea
- Abdominal pain
- Pancreatitis (amylase and/or lipase >200 U/L or radiologic findings)
- Hepatitis (AST and/or ALT >500 U/L)
- Gallbladder hydrops or edema
V. Hematologic involvement (includes ANY of the listed criteria)
- Total white blood cell <4 x10^3/μL
- Anemia (hemoglobin <9 g/dL)
- Platelet count <150,000 /μL
- Hemolysis VI. Mucocutaneous involvement (includes ANY of the listed criteria)
- Bilateral conjunctival injection
- Oral mucosal changes
- Peripheral extremity changes
- Rash or skin ulcers
- 'COVID' toes
- Swollen red cracked lips
- Erythema of palms or soles
- Edema of hands or feet
- Periungual (nails) desquamation
- Conjunctivitis
- Peripheral gangrene
VII. Musculoskeletal involvement (includes ANY of the listed criteria)
- Arthritis or arthralgia involvement
- Myositis or myalgia
- Prior therapy: must have been treated with IVIG (maximum cumulative dose of 5g/kg) 1-7 days prior to enrollment. Patients will be eligible if they have progressive symptoms ≥24 hours after initiation of IVIG or lack of response ≥48 hours after initiation of IVIG. Lack of response is defined as inability wean off of supportive care measures (ie. vasopressors, mechanical ventilation, oxygen support) or lack of improvement in inflammatory markers.
- Prior treatment with immunomodulators (e.g. tocilizumab, etc) is allowed if there was no response or progressive disease 2 days (48 hours) or more after initiation of this therapy.
- Life expectancy ≥ 72 hours
- Legal authorized representative consent
Exclusion Criteria:
- Evidence of acquired or congenital immunodeficiency (due to immunosuppressive therapy, HIV, previous treatment for cancer, etc.)
- History of cancer
- History of previous treatments with MSCs or other cell therapies
- Patient is enrolled in any other IND-sponsored clinical trials for COVID-19
- Evidence of pregnancy or lactation
- Moribund patient not expected to survive > 24 hours
- Patient is receiving Extracorporeal Membrane Oxygenation (ECMO)
- Patient received CPR for this condition
- Patients who have acquired thrombotic risk due to COVID, e.g., VTE, pulmonary embolism, stroke, intracranial hemorrhage, ischemia of an extremity, or prone to thrombotic conditions, e.g., Factor V Leiden mutations, lupus anti-coagulant, etc.
- Patients with history of DMSO allergies
ECG exclusions: prolonged QT interval, changes suggestive of myocardial ischemia, unstable cardiac dys/arrythmia that requires medical stabilization (ie.
unstable supraventricular tachycardia, ventricular tachycardia, or ventricular fibrillation)
- Echocardiogram exclusions: Dilated coronary artery(ies) (z score >2), aneurysms, ectasia, pericardial effusion requiring drainage, or focal wall abnormalities suggestive of myocardial ischemia
- Chest tube
- Concurrent dialysis
- Suspected CNS infection
- Severe bronchospasm requiring continuous bronchodilators
- Pulmonary hemorrhage
- A formal diagnosis of full Kawasaki disease (KD).
- Failure to perform COVID-19 PCR and serology testing prior to IVIG administration.
Sites / Locations
- Emory University School of Medicine
- New York Medical College, Westchester Medical Center (WMC)
- Duke University Medical Center
Arms of the Study
Arm 1
Experimental
hCT-MSC infusion
Doses will be given on days 1, 2, 3, and a fourth, optional dose may be given on day 7 at the discretion of the investigator and the treating physician.